Zelebrudomide
Zelebrudomide is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and Waldenström macroglobulinemia. It is an orally bioavailable proteolysis targeting chimera designed to degrade Bruton's tyrosine kinase along with the immunomodulatory proteins Ikaros and Aiolos.